Reuters, in a story about the anti-obesity drug Acomplia (rimonabant), reported on January 15th that the medicine could be approved by the U.S. Food and Drug Administration “as early as next month.”
Reuters provided no source for its optimistic projection, and …
The magazine Med Ad News, in an article on “future blockbuster drugs,” has named Acomplia its “Product to Watch for 2005″ and said experts feel it has the potential to become the pharmaceutical industry’s once-in-a-decade blockbuster. Below are excerpts from …
The diet drug Acomplia (rimonabant) will not be reimbursed by health insurance in Germany, the European Union’s largest market, according to a decision by the German Ministry of Health published Jan. 11th in the official journal of the
…
Two new Phase III clinical trials of Acomplia — one of them by far the largest yet — are now underway as part of an effort by developer Sanofi-Aventis to assess the potential role of the drug in reducing the …
The Guardian, in the following story published on January 10, 2005, says that while Sanofi is confident it has a winner in the new anti-obesity drug Acomplia, it can expect close scrutiny during the approval process of the side effects. …